Nab-paclitaxel+carboplatin

Phase 3Small molecule

AstraZeneca

Nab-paclitaxel+carboplatin is one of 66 small molecule programs targeting Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Triple-Negative Breast CancerActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

Triple-Negative Breast CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

686 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Nab-paclitaxel+carboplatin

AstraZeneca

Phase 3

1 2

Tecentriq

Roche

Preclinical

9 3

Vizimpro

Pfizer

Preclinical

3 4

Libtayo

Regeneron

Preclinical

3 5

Talzenna

Pfizer

Preclinical

2 6

Folvite

Xylocaine

2 8

Immunotherapy

Bristol-Myers Squibb

Preclinical

5 9

Rilotumumab

Amgen

Preclinical

2 10

Paclitaxel and Carboplatin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Lung Cancer

NCT03775486

Q4 2026

Phase 3Recruiting

Triple-Negative Breast Cancer

NCT04137653

Clinical

Trials by Indication[1]

Lung Cancer1 trial

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT03775486·401 enrolled

Triple-Negative Breast Cancer1 trial

Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT

Recruiting·SShengjing Hospital·Phase 3·NCT04137653·1,498 enrolled

Advanced or Metastatic NSCLC1 trial

A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC

Withdrawn·NNextCure, Inc.·Phase 1/2·NCT04430933

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Nab-paclitaxel+carboplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nab-paclitaxel+carboplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nab-paclitaxel+carboplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

Nab-paclitaxel+carboplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Lung Cancer1 trial

Triple-Negative Breast Cancer1 trial

Advanced or Metastatic NSCLC1 trial

References

Drug Info

Quick Facts

Related News